UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 501

Sortiert nach

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

Clinical pharmacology and therapeutics, 2012-08, Vol.92 (2), p.203-213

2012

Volltextzugriff (PDF)

Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers

Clinical pharmacology and therapeutics, 2007-02, Vol.81 (2), p.194-204

2007

Volltextzugriff (PDF)

Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite

Clinical pharmacology and therapeutics, 2009-01, Vol.85 (1), p.78-85

2009

Volltextzugriff (PDF)

Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial

Clinical pharmacology and therapeutics, 2016-09, Vol.100 (3), p.223-231

2016

Volltextzugriff (PDF)

The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio

Clinical pharmacology and therapeutics, 2018-03, Vol.103 (3), p.521-525

2018

Volltextzugriff (PDF)

Unmasking the dynamic interplay between efflux transporters and metabolic enzymes

International journal of pharmaceutics, 2004-06, Vol.277 (1), p.3-9

2004

Volltextzugriff (PDF)

Hepatic Clearance, but Not Gut Availability, of Erythromycin Is Altered in Patients With End-Stage Renal Disease

Clinical pharmacology and therapeutics, 2010-04, Vol.87 (4), p.465-472

2010

Volltextzugriff (PDF)

The FDA Should Eliminate the Ambiguities in the Current BCS Biowaiver Guidance and Make Public the Drugs for Which BCS Biowaivers Have Been Granted

Clinical pharmacology and therapeutics, 2010-09, Vol.88 (3), p.405-407

2010

Volltextzugriff (PDF)

HIV‐Infected Liver and Kidney Transplant Recipients: 1‐ and 3‐Year Outcomes

American journal of transplantation, 2008-02, Vol.8 (2), p.355-365

2008

Volltextzugriff (PDF)

Immunosuppressant Pharmacokinetics and Dosing Modifications in HIV‐1 Infected Liver and Kidney Transplant Recipients

American journal of transplantation, 2007-12, Vol.7 (12), p.2816-2820

2007

Volltextzugriff (PDF)

An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation

European journal of pharmaceutical sciences, 2018-10, Vol.123, p.502-514

2018

Volltextzugriff (PDF)

Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial

Clinical pharmacology and therapeutics, 2017-03, Vol.101 (3), p.331-340

2017

Volltextzugriff (PDF)

Effect of Single-Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers

Clinical pharmacology and therapeutics, 2010-10, Vol.88 (4), p.540-547

2010

Volltextzugriff (PDF)

Are all measures of liver Kpuu a function of FH, as determined following oral dosing, or have we made a critical error in defining hepatic drug clearance?

European journal of pharmaceutical sciences, 2024-05, Vol.196, p.106753-106753, Article 106753

2024

Volltextzugriff (PDF)

A Holy Grail of Clinical Pharmacology: Prediction of Drug Pharmacokinetics and Pharmacodynamics in the Individual Patient

Clinical pharmacology and therapeutics, 2009-08, Vol.86 (2), p.133-134

Benet, LZ

2009

Volltextzugriff (PDF)

The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein

Clinical pharmacokinetics, 2001, Vol.40 (3), p.159-168

2001

Volltextzugriff (PDF)

Gender effects in pharmacokinetics and pharmacodynamics

Drugs (New York, N.Y.), 1995-08, Vol.50 (2), p.222-239

1995

Volltextzugriff (PDF)

Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results

Clinical pharmacology and therapeutics, 2007-06, Vol.81 (6), p.828-832

2007

Volltextzugriff (PDF)

Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data

Current drug metabolism, 2003-10, Vol.4 (5), p.393

2003

Volltextzugriff (PDF)

Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery

Journal of controlled release, 1999-11, Vol.62 (1-2), p.25-31

1999

Volltextzugriff (PDF)

Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptides and Peptidomimetics

Journal of pharmaceutical sciences, 1998-11, Vol.87 (11), p.1322-1330

1998

Volltextzugriff (PDF)

Role of intestinal P-glycoprotein ( ) in interpatient variation in the oral bioavailability of cyclosporine

Clinical pharmacology and therapeutics, 1997-09, Vol.62 (3), p.248-260

1997

Volltextzugriff (PDF)

Commentary on: “Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide”

Clinical and translational science, 2017-07, Vol.10 (4), p.240-241

2017

Volltextzugriff (PDF)

A Step Closer to Personalized Chemotherapy: Consideration of the Influence of Genetic Variation in Hepatic Uptake Transporters on the Metabolism of CYP3A Substrates

Clinical pharmacology and therapeutics, 2012-11, Vol.92 (5), p.551-552

Benet, L Z

2012

Volltextzugriff (PDF)

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

Molecular carcinogenesis, 1995-07, Vol.13 (3), p.129-134

1995

Volltextzugriff (PDF)

1 – 25 von 501

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(462)
Mit Volltextzugriff
(310)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(384)
Life Sciences & Biomedicine
(362)
Pharmacology & Pharmacy
(294)
Humans
(268)
Biological And Medical Sciences
(228)
Medical Sciences
(223)
Pharmacology. Drug Treatments
(212)
Male
(179)
Animals
(175)
Female
(97)
Physical Sciences
(90)
Kinetics
(87)
Adult
(86)
Chemistry
(86)
Rats
(75)
Chemistry, Multidisciplinary
(61)
General Pharmacology
(59)
Biological Availability
(50)
Chromatography, High Pressure Liquid
(50)
Pharmacokinetics
(49)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers

Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite

Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial

The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio

Unmasking the dynamic interplay between efflux transporters and metabolic enzymes

Hepatic Clearance, but Not Gut Availability, of Erythromycin Is Altered in Patients With End-Stage Renal Disease

The FDA Should Eliminate the Ambiguities in the Current BCS Biowaiver Guidance and Make Public the Drugs for Which BCS Biowaivers Have Been Granted

HIV‐Infected Liver and Kidney Transplant Recipients: 1‐ and 3‐Year Outcomes

Immunosuppressant Pharmacokinetics and Dosing Modifications in HIV‐1 Infected Liver and Kidney Transplant Recipients

An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation

Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial

Effect of Single-Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers

Are all measures of liver Kpuu a function of FH, as determined following oral dosing, or have we made a critical error in defining hepatic drug clearance?

A Holy Grail of Clinical Pharmacology: Prediction of Drug Pharmacokinetics and Pharmacodynamics in the Individual Patient

The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein

Gender effects in pharmacokinetics and pharmacodynamics

Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results

Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data

Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery

Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptides and Peptidomimetics

Role of intestinal P-glycoprotein ( ) in interpatient variation in the oral bioavailability of cyclosporine

Commentary on: “Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide”

A Step Closer to Personalized Chemotherapy: Consideration of the Influence of Genetic Variation in Hepatic Uptake Transporters on the Metabolism of CYP3A Substrates

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

Suchergebnisse filtern